Executive Summary: Ophthalmic gene therapy clinical trials aim to correct or replace genes in the eye to slow, halt, or reverse inherited retinal diseases. Gene therapy has rapidly moved from concept to clinic in ophthalmology. The approval of voretigene neparvovec (Luxturna) for RPE65‑mediated retinal dystrophy demonstrated that targeted genetic correction could improve functional vision, validate decades of research, and open the door for numerous retinal gene therapy programs.
Today, ophthalmology ranks among the leading areas for planned and ongoing gene therapy studies. Medpace helps to accelerate these trials with a cross‑functional model that connects ophthalmology Sponsors to medical directors, retinal surgeons, imaging experts, regulatory strategists, and operational teams with specialized gene therapy experience. This structure is particularly important because gene therapy is typically delivered as a single administration with follow‑up extending up to 15 years, demanding robust long‑term safety monitoring, sensitive outcome measures to assess durable and sustained efficacy, and durable long-term site and patient engagement. By combining ophthalmology and cell and gene therapy capabilities, our unique blend of scientific depth and operational discipline helps Sponsors de‑risk development and move promising therapies forward.
Why Ophthalmology Gene Therapy Trials Are Unique
Ophthalmology gene therapy clinical trials differ from conventional ophthalmic drug studies because they target the genetic root cause of disease using single dose interventions delivered directly into ocular tissues, often with decade-long follow‑up requirements and highly specialized imaging and functional endpoints.
Unlike many ophthalmic drugs, gene therapies are usually designed for monogenic or genetically defined retinal diseases. Sponsors must define the mutation or genotype being treated, then locate small, geographically dispersed patient populations who meet both clinical and genetic criteria. Many eligible patients have few or no approved treatment options. This results in strong interest, but also requires careful education about benefits, risks, and uncertainty.
From a technical perspective, gene therapy products often use bio‑engineered AAV vectors with organ‑specific promoters to infect target retinal cells and drive transgene expression. The eye’s immune‑privileged subretinal space allows local delivery of very small volumes with minimal systemic exposure, limiting neutralizing antibody formation and enabling treatment of the second eye—an important distinction from systemic gene therapy approaches.
Harnessing Scientific Innovation in Retinal Gene Therapy Design
Retinal gene therapy trial design requires a strategic approach that aligns disease genetics, delivery techniques, safety considerations, and imaging-based efficacy endpoints to detect meaningful clinical outcomes in small patient populations.
Key scientific considerations include:
- Disease genetics and mutuation-specific targeting strategies
- Dosing strategies and long-term safety monitoring plans
- Imaging-anchored efficacy endpoints for retinal assessment
- Mutation-agnostic and RNA-based therapeutic approaches
- Delivery route selection based on efficacy and safety goals
Current delivery approaches may include:
- Subretinal administration
- Most commonly used in current retinal gene therapy trials
- Limits systemic exposure and concentrates vector delivery to the retina
- Requires experienced vitreoretinal surgeons and specialized OR infrastructure
- Suprachoroidal delivery
- May avoid vitrectomy procedures
- Emerging as an alternative route for retinal targeting
- Intravitreal administration
- Easier to administer
- Currently under active investigation
- May increase risk of systemic exposure and immune-mediated inflammation
Operational Strategies to Run Complex Ophthalmology Gene Therapy Trials
Operational execution of ophthalmology gene therapy trials requires carefully selected sites, specialized imaging capabilities, trained technicians, and logistics that minimize patient burden while maintaining protocol integrity.
Many ophthalmology sites lack all the equipment needed for cutting-edge retinal gene therapy studies. Trials may require microperimetry, visual field analyzers, -70 °C freezers, validated visual acuity charts, and advanced imaging modalities, alongside emerging tools and technology. Strategies such as assigning the same technician to perform all visual acuity assessments for a given participant can improve reproducibility, while standardized training documents and certification processes help harmonize performance across global sites.
Rare inherited retinal diseases present additional recruitment and retention challenges. Eligible patients may live far from specialized centers, and many have limited prior trial exposure. With our vast experience in rare disease and integrated technology, Medpace can leverage our data to identify geographic pockets of patients, then strategically select central dosing sites with gene therapy experience and satellite sites that can handle long-term follow-up. By easing travel and communication barriers, Sponsors keep highly motivated, and a vulnerable patient population engaged throughout extended follow-up periods.
Regulatory Pathways for Ophthalmic Gene Therapy Success
Regulatory strategy for ophthalmic gene therapy hinges on early engagement with agencies, thoughtful use of expedited designations, and carefully constructed endpoint and safety packages that reflect both advanced therapy guidelines and ophthalmology specific expectations.
In the US, Sponsors can seek early interaction with the FDA through INTERACT or pre‑IND meetings and may qualify for programs like Regenerative Medicine Advanced Therapy (RMAT) designation or Breakthrough Therapy designation for serious, sight threatening conditions.
In Europe, tools such as the PRIME scheme and orphan drug designation offer additional guidance, fee reductions, and potential timeline advantages when criteria are met. Our regulatory experts assist Sponsors with global strategies, from defining which jurisdictions to prioritize to sequencing scientific advice, IND/CTA submissions, and requests for special designations.
Our teams have prepared INDs, BLAs, MAAs, and briefing packages across ophthalmology and advanced therapies, giving Sponsors access to precedents and lessons learned from prior gene therapy reviews.
Partner With Medpace to Accelerate Vision Saving Therapies
Medpace’s integrated ophthalmology and gene therapy expertise enables Sponsors to move innovative retinal gene therapies from concept to clinic through a single, full-service CRO partner. By combining scientific depth, operational excellence, and proactive regulatory strategy, Medpace helps streamline development for complex ophthalmic programs.
Our medical directors and medical monitors bring decades of research and development, clinical and surgical experience across inherited and age‑related retinal diseases, while our cell and gene therapy experts have supported more than 160 cell and gene therapy trials globally.
As gene therapy reshapes the treatment landscape for inherited and severe retinal diseases, Sponsors face increasing complexity, including:
- Rare disease recruitment challenges
- Highly specialized imaging and functional testing
- Complex surgical delivery techniques
- Multi-year safety and efficacy assessment requirements
Medpace addresses these challenges through cross‑functional teams spanning ophthalmology, cell and gene therapy, central and bioanalytical laboratories, and global regulatory affairs. For Sponsors advancing the next generation of ophthalmic gene therapies, partnering with Medpace can be a decisive step toward delivering vision restoring treatments to patients worldwide.
Meet The Expert:
Marco Tangelder, MD, PhD
Sr. Medical Director
Dr. Marco Tangelder is a clinical epidemiologist with more than 30 years of academic, pharmaceutical and biotech industry R&D experience, for a broad range of indications, including development of gene therapy for hemophilia, and ophthalmology. Dr. Tangelder received both his medical degree and PhD at the University of Utrecht in the Netherlands and received his Master’s in Pharmaceutical Medicine at the Karolinska Institute in Stockholm, Sweden
Prior to joining Medpace in 2017, Dr. Tangelder held key roles in various biotechnology and pharmaceutical companies in which he was responsible for translational medicine, phase 1-4 clinical development programs, and regulatory approvals. Specifically, Dr. Tangelder served at ThromboGenics where he contributed to the BLA and MAA submissions of ocriplasmin (Jetrea®) leading to approval for the treatment of symptomatic vitreomacular adhesion, and where he also developed clinical trials for diabetic retinopathy, diabetic macular edema, and metamorphopsia.
Prior to joining Medpace, Dr. Tangelder led at uniQure the clinical development of gene therapy for hemophilia and contributed to preclinical development and translational research of gene therapy constructs for various rare disease indications.